An announcement from Renalytix ( (GB:RENX) ) is now available.
Renalytix has reported strong financial and operational progress in its half-year report for FY25, with revenues of $1.3 million and a significant increase in commercial insurance reimbursed testing revenue. The company has expanded its doctor base and reduced operational costs, demonstrating a 56.5% reduction in administrative expenses. Renalytix is on track to meet or exceed its revenue growth targets, with plans to expand its kidneyintelX.dkd distribution through new insurance payors and care networks. The company’s efforts are supported by Medicare coverage, international clinical guidelines, and a growing number of pharmaceutical collaborations, positioning it well in the precision medicine industry.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing the clinical management of kidney disease to improve patient outcomes. The company offers kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic kidney disease, particularly targeting the diabetic kidney disease market in the United States.
YTD Price Performance: 13.75%
Average Trading Volume: 404
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $38.7M
For a thorough assessment of RENX stock, go to TipRanks’ Stock Analysis page.